TLR3 and TLR4 as potential clinically biomarkers of cardiovascular risk in coronary artery disease (CAD) patients

Heart and Vessels

Volumn 29, Issue 5, 2014, Pages 690-698

  Shao, Liang ^a,b,c   Zhang, Ping ^d   Zhang, Yong ^b   Lu, Qun ^a,b,c   Ma, Aiqun ^a,b,c  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c Key Laboratory of Molecular Cardiology   (China)

^d UNION HOSPITAL   (China)

Author keywords

Coronary angiography; Coronary artery disease; Innate inflammation; Toll like receptor

Indexed keywords

AUTACOID; BIOLOGICAL MARKER; MESSENGER RNA; MYD88 PROTEIN, HUMAN; MYELOID DIFFERENTIATION FACTOR 88; TLR3 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4;

AGED; ANGIOCARDIOGRAPHY; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; CORONARY STENOSIS; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION;

AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY STENOSIS; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; MYELOID DIFFERENTIATION FACTOR 88; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 4;

EID: 84929504378     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-013-0421-3     Document Type: Article

References (29)

1. World Health Organization (2011) Cardiovascular diseases (CVDs). http://www.who.int/mediacentre/factsheets/fs317/en
2. Ross R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340:115–126
3. Grüntzig AR, Senning A, Siegenthaler WE (1997) Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 12:301(2)61–68
4. Nagai T, Hirano T, Tsunoda M (2012) Left circumflex coronary artery is protected against no-reflow phenomenon following percutaneous coronary intervention for coronary artery disease. Heart Vessels. doi:10.1007/s00380-012-0281-2
5. Hansson GK, Libby P, Schonbeck U, Yan ZQ (2002) Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 91:281–291
6. Felton CV, Crook D, Davies MJ, Oliver MF (1997) Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Arterioscler Thromb Vasc Biol 17(7):1337–1345
7. Heine H, Lien E (2003) Toll-like receptors and their function in innate and adaptive immunity. Int Arch Allergy Immunol 130:180–192
8. Cole JE, Mitra AT, Monaco C (2010) Treating atherosclerosis: the potential of Toll-like receptors as therapeutic targets. Expert Rev Cardiovasc Ther 8(11):1619–1635
9. Cole JE, Georgiou E, Monaco C (2010) The expression and functions of Toll-like receptors in atherosclerosis. Mediators Inflamm 2010:393–946. doi:10.1155/2010/393946
10. Lee J, Lim E, Park D, Lee S, Kim J, Baek S (2008) A combination of Lox-1 and Nox1 regulates TLR9-mediated foam cell formation. Cell Signal 20(12):2266–2275
11. Katoh S, Honda S, Watanabe T (2013) Atrial endothelial impairment through Toll-like receptor 4 signaling causes atrial thrombogenesis. Heart Vessels. doi:10.1007/s00380-013-0369-3
12. Doyle S, O’Connell R, Miranda G (2004) Toll-like receptors induce a phagocytic gene program through p38. J Exp Med 199(1):81–90
13. Michelsen KS, Wong MH, Shah PK (2004) Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 101(29):10679–10684
14. Cole JE, Navin TJ, Cross AJ (2011) Unexpected protective role for Toll-like receptor 3 in the arterial wall. Proc Natl Acad Sci USA 108(6):2372–2377
15. Hansson GK, Robertson A-KL, Söderberg-Nauclér C (2006) Inflammation and atherosclerosis. Annu Rev Pathol 1:297–329
16. Gordon S, Martinez FO (2010) Alternative activation of macrophages: mechanism and functions. Immunity 32(5):593–604
17. Edfeldt K, Swedenborg J, Hansson G, Yan Z (2002) Expression of Toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105(10):1158–1161
18. Yang X, Murthy V, Schultz K, Tatro JB, Fitzgerald KA, Beasley D (2006) Toll-like receptor 3 signaling evokes a proinflammatory and proliferative phenotype in human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 291(5):H2334–H2343
19. Cole JE, Navin TJ, Cross AJ, Goddard ME, Alexopoulou L, Mitra AT (2011) Unexpected protective role for Toll-like receptor 3 in the arterial wall. Proc Natl Acad Sci USA 108(6):2372–2377
20. Guarda G, Braun M, Staehli F, Tardivel A, Mattmann C, Förster I (2011) Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34 (2):213–223
21. Jialal I, Kaur H (2012) The role of Toll-like receptors in diabetes-induced inflammation: implications for vascular complications. Curr Diab Rep 12(2):172–179
22. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr (1997) A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 88(6640):394–397
23. Quan J, Liu J, Gao X (2013) Palmitate induces interleukin-8 expression in human aortic vascular smooth muscle cells via Toll-like receptor 4/NF-κB pathway. J Diabetes. doi:10.1111/1753-0407.12073
24. Richards MR, Black AS, Bonnet DJ, Barish GD, Woo CW, Tabas I, Curtiss LK, Tobias PS (2013) The LPS2 mutation in TRIF is atheroprotective in hyperlipidemic low-density lipoprotein receptor knockout mice. Innate Immun 19(1):20–29. doi:10.1177/1753425912447130
25. Lundberg AM, Ketelhuth DF, Johansson ME, Gerdes N, Liu S, Yamamoto M, Akira S, Hansson GK (2013) Toll-like receptor 3 and 4 signalling through the TRIF and TRAM adaptors in haematopoietic cells promotes atherosclerosis. Cardiovasc Res 99(2):364–73
26. Lee JY, Ye J, Gao Z, Youn HS, Lee WH, Zhao L, Sizemore N, Hwang DH (2003) Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J Biol Chem 278(39):37041–37051
27. Rowe DC, McGettrick AF, Latz E, Monks BG, Gay NJ, Yamamoto M, Akira S, O’Neill LA, Fitzgerald KA, Golenbock DT (2006) The myristoylation of TRIF-related adaptor molecule is essential for Toll-like receptor 4 signal transduction. Proc Natl Acad Sci USA 103(16):6299–6304
28. Methe H, Kim JO, Kofler S, Nabauer M, Weis M (2005) Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. Arterioscler Thromb Vasc Biol 25(7):1439–1445 Epub 2005 Apr 28
29. Abe M, Matsuda M, Kobayashi H, Miyata Y, Nakayama Y, Komuro R, Fukuhara A, Shimomura I (2008) Effects of statins on adipose tissue inflammation: their inhibitory effect on MyD88-independent IRF3/IFN-beta pathway in macrophages. Arterioscler Thromb Vasc Biol 28(5):871–7. doi:10.1161/ATVBAHA.107.160663